Peter Hofland, PhD has not received any gifts yet
Published today Online at Medscape Internal Medicine, Art Caplan PhD, a Bioethicist at the University of Pennsylvania, Department of Medical Ethics and Health Policy, commented on the question…Continue
Each year, more than 440,000 Americans die from smoking. Eight million Americans live with at least one serious chronic disease from smoking. The cost to U.S economy is $193 billion a year, with nearly $96 billion in direct medical costs and an additional $97 billion in lost productivity. But change is looming on the horizon.
January 2014 marks the 50th anniversary of the first Surgeon General's report on Smoking and Health. On January 11, 1964, Luther L. Terry,…Continue
The PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) starts its patient accrual phase. This trial is a double-blind, randomized study and will enroll approximately 440 patients with metastatic pancreatic cancer. A majority of patients will be recruited at clinical trial sites across the United States, with additional sites in Canada, Europe and Israel participating. Eligible patients will be randomized 2 to 1 to the treatment arm of 3 doses of 90Y-clivatuzumab tetraxetan (…Continue
The U.S. Food and Drug Administration (U.S.FDA) has approved trametinib (Mekinist®; Glaxosmithkline/GSK) for use in combination with dabrafenib (Tafinlar®;Glaxosmithkline/GSK) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved companion…Continue
Researchers at the University of Cincinnati (UC) Cancer Institute have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer (NSCLC) with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with that condition.
These findings are presented via poster at the American Association for Cancer Research (AACR)–International Association for the…Continue
In many types of cancer cells from the primary tumor can intravasate into the bloodstream as circulating tumor cells or CTCs. These CTCs can then interact with the receptor-bearing endothelial cell wall. The process is similar to leukocyte extravasation - the flow of blood or lymph-fluid into surrounding tissue during inflammation.
Now for the first time biomedical engineers at Cornell University inIthaca in New York, NY have discovered a new way to destroy these…Continue
Targeting cancer stem cells (CSCs) - cells from which malignant brain tumors are believed to originate and regenerate- with immunotherapy may be an effective means to prevent recurrences in glioblastoma multiforme (GBM). Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of…Continue
Finding a cure for cancer - the second-leading cause of death in the United States - was what the American people really wanted in 1970. In response, President Nixon, in the January 1971 State of the Union address said: "I will also ask for an appropriation of an extra $100 million to launch an intensive campaign to find a cure for cancer, and I will ask later for whatever additional funds can effectively be used. The time…Continue
Glioblastoma multiform or GBM, the brain cancer that killed Senator Edward M. Kennedy of Massachusetts and kills approximately 13,000 Americans a year, is aggressive and incurable. Now a team of researchers at Northwestern University (Evanston, Illinois) is the team first to demonstrate delivery of a drug that turns off a critical gene in this complex cancer, increasing survival rates significantly in…Continue
According to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting, being held in Atlanta,September 22-25, 2013, early-stage breast cancer patients who receive external beam therapy or XRT are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies.
Various studies have shown that…Continue
Results of a study presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting held in Atlanta, September 22-25, 2013 shows that Sulfasalazine (Azulfidine®, Pfizer), a drug commonly prescribed to reduce diarrhea in patients with rectal bleeding and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area. The study…Continue